Business Context and Reporting Period
This Form 6-K, filed on June 17, 2025, by BioNTech SE (the "Buyer"), discloses the entry into a Purchase Agreement dated June 12, 2025, with CureVac N.V. (the "Company"). The agreement outlines a plan for BioNTech to acquire CureVac through a public exchange offer followed by a post-offer reorganization. Upon completion, CureVac will cease to be a publicly traded company, and its shares will be deregistered under the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed acquisition rather than reporting standard operational financial metrics (revenue, profit, cash flow) for the period.
- Offer Consideration: CureVac shareholders will receive BioNTech American Depositary Shares (ADS) based on an Exchange Ratio. The ratio is calculated by dividing $5.4641 by the 10-day volume-weighted average price (VWAP) of BioNTech ADSs preceding the offer expiration.
- Exchange Ratio Collars:
- If BioNTech ADS VWAP is $\ge$ $126.55, the ratio is fixed at 0.04318.
- If BioNTech ADS VWAP is $\le$ $84.37, the ratio is fixed at 0.06476.
- Termination Fees:
- CureVac to pay BioNTech: $43,750,000 (triggered by superior proposals, adverse recommendation changes, or willful breach of non-solicitation).
- BioNTech to pay CureVac: $62,500,000 (triggered by failure to obtain antitrust approvals).
- Equity Award Treatment: Outstanding CureVac performance stock units (PSUs), restricted stock units (RSUs), and options will generally vest or be settled in cash based on the "Company Value Per Share" at closing, subject to specific performance conditions.
Material Changes and Transaction Conditions
The filing represents a material change in corporate structure for CureVac, transitioning from an independent public entity to a subsidiary of BioNTech. The transaction is subject to several critical conditions:
- Minimum Condition: Tendering of at least 80% of CureVac's issued and outstanding shares (reducible to 75% under certain circumstances).
- Regulatory Approvals: Receipt of required antitrust and other regulatory approvals.
- Shareholder Approval: Adoption of resolutions by CureVac shareholders at an Extraordinary General Meeting (EGM) approving the reorganization and appointing BioNTech-designated board members.
- Timeline: The offer must be consummated by March 12, 2026 (the "End Date"), unless extended for antitrust reasons.
Guidance, Outlook, and Risks
The filing contains no financial guidance or operational outlook for either company. It focuses exclusively on the mechanics and risks of the proposed transaction.
- Management Commentary: The Company has agreed not to solicit alternative acquisition proposals and has committed to recommending the offer to shareholders.
- Corporate Governance: Upon closing, the CureVac management board will be reconstituted with individuals designated by BioNTech. The supervisory board will include three BioNTech designees and two independent members.
- Risks and Contingencies:
- Failure to satisfy offer conditions (tender threshold, regulatory approvals, shareholder vote).
- Termination of the agreement due to legal restraints, breaches, or superior proposals.
- Disruption to business operations and diversion of management attention.
- Uncertainty regarding the timing of the exchange offer and reorganization.
Investor Verification Checklist
- Verify the final Exchange Ratio once the BioNTech ADS VWAP is calculated near the offer expiration.
- Monitor the status of antitrust and regulatory approvals, which are a condition precedent to closing.
- Confirm the outcome of the CureVac Extraordinary General Meeting (EGM) regarding shareholder approval.
- Review the upcoming Registration Statement on Form F-4 and Tender Offer Statement on Schedule TO for detailed risk factors and offer terms.
- Assess the impact of the transaction on outstanding CureVac equity awards (PSUs, RSUs, Options) based on the specific vesting and settlement formulas provided.